Hutchmed China Limited Adr (HCM)

전일 마감가:

$17.82

열려 있는:

$17.83

하루 거래량:

4,385

시가총액:

$3.08B

수익:

$838.00M

순이익/손실:

$100.78M

주가수익비율:

-71.26

EPS:

-0.25

순현금흐름:

$186.65M

1주 성능:

-0.11%

1개월 성능:

-5.02%

6개월 성능:

+5.58%

1년 성능:

+59.55%

1일 변동 폭

$17.67

$18.00

52주 변동 폭

$10.97

$21.92

Hutchmed China Limited Adr Stock (HCM) Company Profile

명칭

Hutchmed China Limited Adr

부문

Healthcare (1191)

산업

Drug Manufacturers - Specialty & Generic (1)

전화

-

주소

-

직원

0

트위터

@hchimed

다음 수익 날짜

2024-06-10

최신 SEC 제출 서류

HCM's Discussions on Twitter

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2023-11-24	업그레이드	Deutsche Bank	Hold → Buy
2022-05-04	다운그레이드	Deutsche Bank	Buy → Hold
2021-09-22	다운그레이드	Goldman	Buy → Neutral
2021-08-03	개시	Jefferies	Buy
2020-10-02	개시	Deutsche Bank	Buy
2020-03-13	개시	Cantor Fitzgerald	Overweight
2020-02-20	개시	Goldman	Buy
2019-11-19	개시	CLSA	Buy
2019-10-23	재확인	BofA/Merrill	Buy
2019-07-05	개시	Macquarie	Outperform

모두보기

Hutchmed China Limited Adr 주식(HCM)의 최신 뉴스

HUTCHMED to Announce 2024 Half-Year Financial Results

GlobeNewswire Inc.

HUTCHMED: Data at EHA 2024 heighten focus on sovleplenib - Research Tree

Research Tree

Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024

GlobeNewswire Inc.

HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda

GlobeNewswire Inc.

Down -25.73% in 4 Weeks, Here's Why HUTCHMED (HCM) Looks Ripe for a Turnaround - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Down -25.73% in 4 Weeks, Here's Why HUTCHMED (HCM) Looks Ripe for a Turnaround - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Hutchmed China Limited Adr (HCM) 재무 분석

Hutchmed China Limited Adr (HCM) 매출 2024

Hutchmed China Limited Adr (HCM) 순이익 2024

Hutchmed China Limited Adr (HCM) 현금흐름 2024

Hutchmed China Limited Adr (HCM) 주당 순이익 2024